Cerus

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cerus excels in Q4 with record growth and strategic milestones

Cerus delivered a strong performance in Q4 2022, driven by the success of the INTERCEPT Blood System and robust product revenue growth.
While facing challenges in inventory management and international expansion, the company's focus on innovation and upcoming milestones position it for future growth.
Opportunities in regulatory submissions, market expansion, and achieving cash flow breakeven in 2023 underscore Cerus' potential for sustained success and market leadership.

Cerus reports Q1 revenue dip, eyes China growth opportunities

Cerus navigated Q1 with a focus on financial stability, product adoption, and global market expansion. Despite revenue challenges, the company's strategic initiatives and successful debt refinancing position it for future growth. Addressing inventory management, label expansion, and market-specific hurdles will be key to unlocking opportunities.

Cerus (CERS) reports robust Q2 performance amidst growth challenges

Cerus delivered a strong performance in Q2, marked by revenue growth, improved margins, and effective cost management.
While facing challenges in U.S. customer ordering patterns and market penetration, the company remains well-positioned for growth.
With a focus on operational efficiency, product development, and market expansion, Cerus is poised to capitalize on growth opportunities.
The company's financial strength, coupled with strategic initiatives, sets a positive trajectory for continued progress and success.

Cerus reports robust Q3 sales, adjusts revenue guidance for 2023

Cerus shows strong sales growth, positive market sentiment, and progress in key trials. Challenges include revenue guidance adjustment due to delayed sales agreement. Opportunities lie in expanding product demand and achieving EBITDA breakeven.

Cerus surpasses 16 million kits sold, expects double-digit growth

Cerus delivered a strong performance in Q4 2023, surpassing 16 million kits sold and achieving positive non-GAAP adjusted EBITDA for the first time.
The company's focus on the platelet franchise and IFC business yielded growth, setting the stage for continued expansion in 2024.
While facing challenges in revenue expectations and market competition, Cerus remains well-positioned to capitalize on growth opportunities.
Guidance for 2024 indicates a positive outlook with expectations of sustained growth in the INTERCEPT platelet business and IFC revenue.

Cerus reports robust Q1 earnings, eyes international growth opportunities

Cerus' Q1 2024 earnings call highlighted strong financial performance, positive trial results, and reiterated revenue guidance. The company is focused on achieving breakeven non-GAAP adjusted EBITDA for the year. Challenges include regulatory progress and working capital adjustments, while opportunities exist in international market expansion and operational optimization.

Cerus excels in Q2 2024, raises revenue guidance amid global expansion

Cerus demonstrates strong financial performance, driven by global adoption of INTERCEPT. Focus on expanding sales in key markets and addressing analyst queries to sustain growth momentum. Future growth prospects look promising with a commitment to transparency and investor engagement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cerus Corporation (NASDAQ:CERS ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman - COO Kevin Green - CFO Conference Call Participants Matthew Park - Cantor Fitzgerald Colin Wells - Stifel Jacob Johnson - Stephens Joshua Jennings - TD Cowan Vidyun Bais - BTIG William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Third Quarter 2024 Earnings Conference Call.

Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript

Cerus (CERS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024. Total revenue for the three and nine months ended September 30, 2024 was comprised of (in thousands, except %): Three Months Ended   Nine Months Ended September 30, Change   September 30, Change 2024   2023   $   % 2024   2023   $   % Product Revenue $ 46,017 $ 39,772 $ 6,245   16 % $ 129,461 $ 109,599 $ 19,862   18 % Government Con.

Cerus Corporation Announces Third Quarter 2024 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit t.

Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting, taking place in Houston, Texas from October 19 through October 22. This year's AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies. The following is a select list of Cerus-related presenta.

Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: U.S. – New $248 million BARDA contract supports program beyond U.S. Phase 3 studies through anticipated PMA licensure and into commercialization Europe – CE Mark review has been concluded without approval; assessing strategy for anticipated future filing “We are pleased with the progress we have made with our U.S. RBC program, which.

Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

Cerus Corporation (NASDAQ:CERS ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman - COO Kevin Green - CFO Conference Call Participants Ross Osborne - Cantor Fitzgerald Jacob Johnson - Stephens Eric Anderson - TD Cowen Vidyun Bais - BTIG William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Second Quarter 2024 Earnings Conference Call.

Cerus Corporation (CERS) Q2 2024 Earnings Call Transcript

Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.07 per share a year ago.

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %): Three Months Ended   Six Months Ended June 30, Change June 30, Change 2024 2023 $ % 2024 2023 $ % Product Revenue $ 45,079 $ 38,853 $ 6,226   16 % $ 83,444 $ 69,827 $ 13,617   20 % Government Contract Revenue   5,440   8,875   (3,435.

Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the.

Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier.

Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed.

Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. For 2024, the focus of this day is on all blood donors, essential for ensuring patients have access to blood transfusion, as well as on efforts to overcome challenges and.

Cerus Corporation Celebrates World Blood Donor Day 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29th. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital.

Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

Cerus Corporation (NASDAQ:CERS ) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President of Regulatory and Quality Conference Call Participants Emily Christy - Stifel Jacob Johnson - Stephens Ross Osborne - Cantor Fitzgerald William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation First Quarter 2024 Earnings Conference Call.

Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total revenue was comprised of (in thousands, except %): Three Months Ended March 31, Change 2024   2023   $   % Product Revenue $ 38,365 $ 30,974 $ 7,391   24% Government Contract Revenue   5,030   7,502   (2,472 ) -33% Total Revenue $ 43,395 $ 38,476 $ 4,919   13% U.S. ReCePI Phase 3 clinical trial succes.

Cerus Corporation Announces First Quarter 2024 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Inv.

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventori.

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensiti.

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Cerus Corporation (NASDAQ:CERS ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Kevin Green - Vice President Finance and Chief Financial Officer Vivek Jayaraman - Chief Operating Officer Carol Moore - Senior Vice President of Regulatory Affairs and Quality Conference Call Participants Jacob Johnson - Stephens Emily Christy - Stifel Operator Good day ladies and gentlemen. Thank you for standing by and welcome to the Cerus Corporation's Fourth Quarter and Full Year 2023 Earnings Conference Call.

Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-quarter 2023 and full-year 2023 total revenue was comprised of (in thousands, except %):   Three Months Ended           Twelve Months Ended           December 31,   Change   December 31,   Change     2023     2022   $   %     2023     2022   $   % Product Revenue $ 46,768   $ 44,034   $ 2,734     6 %.

Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, plea.

Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST. A live webcast of the TD Cowen presentation will be available here and the replay will be available on.

Cerus Corporation to Participate in Upcoming Investor Conferences

AbCellera Biologics

Taysha Gene Therapies

Small- to mid-cap growth stocks largely struggled over the past two years. With the Federal Reserve likely to pivot on interest rates this year, this group may be poised for a trend reversal.

3 Growth Stocks That Could Go Parabolic in 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-year 2024. Cerus' unaudited preliminary product revenue for the fourth quarter of 2023 totaled $46.8 million, representing an increase of 6% over the $44.0 million recognized during the fourth quarter of 2022 and 18% sequentially. The Company expects its unaudited preliminary full-year 2023 product.

News for Cerus Stock (CERS)